07

Publications

May '26

BH-200 (nelivaptan), a Vasopressin V1b Receptor Antagonist, in Genetically Defined Subgroups of MDD: Precision Targeting of HPA-Axis Dysregulation in the OLIVE Phase 2 Program

American Society of Clinical Psychopharmacology,
May 2026

May '26

Pooled Individual Patient Data Analysis of Three Phase 2 Trials Supports Vasopressin V1b Receptor Antagonism (BH-200 250 mg BID) as an Antidepressant Mechanism for the Treatment of Major Depressive Disorder (MDD)

American Society of Clinical Psychopharmacology,
May 2026

May '26

Genetically Defined Subgroup Analysis Reveals Differential response to Vasopressin V1b Antagonism in Patients with MDD Pre-exposed to Antidepressant in the current episode: Post-hoc Analysis of the Phase 2 OLIVE Trial

American Society of Clinical Psychopharmacology,
May 2026

May '26

A phase 2 clinical trial exploring efficacy and safety of the vasopressin V1b antagonist BH-200, a treatment for MDD, evaluating the performance of a genetic classification tool to identify a subset of patients with larger improvement

American Society of Clinical Psychopharmacology,
May 2026

May '26

Truncated Depression Rating Scale Outcomes in the OLIVE Trial Exploring a V1bR Antagonist and a Genetic Selection Tool

American Psychiatric Association Annual Meeting,
May 2026

May '26

Antidepressant Efficacy of BH-200 in Patients Classified by a Genetic Selection Tool: Secondary Endpoint Results from the OLIVE Trial

American Psychiatric Association Annual Meeting
May 2026

Jan '26

Efficacy and safety of BH-200, a selective vasopressin V1b receptor antagonist, in the treatment of genetically defined subgroups of patients with major depressive disorder (MDD)

American College of Neuropsychopharmacology Annual Meeting,
January 2026